An ongoing dialogue on HIV/AIDS, infectious diseases,
October 23rd, 2011
TB, Timing of Antiretroviral Therapy, and Being a Lumper Rather Than a Splitter
Three key papers on timing of ART in patients with TB have just been published in the New England Journal of Medicine.
Fortunately, Carlos Del Rio has done a bang-up job summarizing them in Journal Watch AIDS Clinical Care.
And if you’re wondering how we got our title for Carlos’ piece, here’s an e-mail between our Executive Editor to me a few weeks ago:
Later this month, NEJM will be publishing three articles on the timing of ART initiation relative to TB treatment. I assume we should cover these?
To which I responded:
Yep. And they all can be summarized as follows: “TB + low CD4 = start ART sooner rather than later”.
Yes, there are lots more data from these studies than this simple equation, but my response was a reminder that, despite being a thrice-certified ID specialist, I tend to be more of a lumper rather than a splitter — which makes me feel somewhat deficient in our field.
Of course even the less detail-obsessed ID docs like me probably score pretty high on the OCD-meter, so I can take some comfort in that.
Comments are closed.
Paul E. Sax, MD
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- Endless Recertification in Medicine — Some Thoughts About the Tests We Take
- Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Modify Treatment Guidelines?
- My Vote for the Weirdest Antibiotic on the Planet
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- Really Rapid Review — Brisbane IAS 2023
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
- Missed Chances for Screening in Persons Newly Diagnosed with HIV: New York City, 2018–2022
- Arboviral Disease Surveillance in the U.S.
- Observations from ID and Beyond: Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Change Treatment Guidelines?
- Risk for C. difficile Infection Varies Widely with Choice of Antibiotic
- Mpox in Persons with Previous Infection or Vaccination
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster